Evidence map›Paper›PMID 36366424›Full record

ArticleViruses2022

Blood Center Testing Allows the Detection and Rapid Treatment of Acute and Recent HIV Infection.

Karin van den Berg, Marion Vermeulen, Sonia Bakkour, Mars Stone, Genevieve Jacobs, Cynthia Nyoni, Coreen Barker, Christopher McClure, Darryl Creel, Eduard Grebe and 6 more

Open access · goldAbstract read
In one paragraph

Article in Viruses, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 2 countries.

Karin van den BergSouth African National Blood Service, Johannesburg 3610, South Africa.ORCID 0000-0001-9805-8013
Marion VermeulenSouth African National Blood Service, Johannesburg 3610, South Africa.ORCID 0000-0003-4383-4526
Sonia BakkourVitalant Research Institute, San Francisco, CA 94118, USA.
Mars StoneVitalant Research Institute, San Francisco, CA 94118, USA.
Genevieve JacobsSouth African National Blood Service, Johannesburg 3610, South Africa.
Cynthia NyoniSouth African National Blood Service, Johannesburg 3610, South Africa.
Coreen BarkerClinical HIV Research Unit, University of the Witwatersr, Johannesburg 2092, South Africa.
Christopher McClureRTI International, Rockville, MD 20852, USA.
Darryl CreelRTI International, Rockville, MD 20852, USA.
Eduard GrebeVitalant Research Institute, San Francisco, CA 94118, USA.
Nareg RoubinianVitalant Research Institute, San Francisco, CA 94118, USA.
Ute JentschSouth African National Blood Service, Johannesburg 3610, South Africa.
Brian CusterVitalant Research Institute, San Francisco, CA 94118, USA.ORCID 0000-0001-6251-366X
Michael P BuschVitalant Research Institute, San Francisco, CA 94118, USA.ORCID 0000-0002-1446-125X
Edward L MurphyVitalant Research Institute, San Francisco, CA 94118, USA.
On Behalf Of The Recipient Epidemiology And Donor Evaluation Study Reds-Iii South Africa International Program
South African National Blood Service · ZAUniversity of California, San Francisco · USRTI International · USKaiser Permanente · USStellenbosch University · ZAUniversity of the Witwatersrand · ZA

Funding

Research training in HIV-related transfusion medicine and hematology in South AfricaD43TW010345 · FIC · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI UTE JENTSCH, EDWARD L MURPHY · 2017 to 2026
$3.0M
FIC NIH HHS D43 TW010345FIC NIH HHS D43-TW010345NHLBI NIH HHS HHSN268201100002INHLBI NIH HHS HHSN268201100009I
6 · The paper itself

Abstract

Blood donations in South Africa are tested for HIV RNA using individual donation NAT (ID-NAT), allowing detection and rapid antiretroviral therapy (ART) of acute HIV infections. We enrolled a cohort of acute and recent HIV-infected blood donation candidates in South Africa in 2015-2018, measured HIV antibody, ID-NAT, and recency of infection <195 days (Sedia LAg) at enrollment and initiated early ART. A small cohort of HIV elite controllers was followed without treatment. HIV reservoir measurements included ultrasensitive plasma RNA, cell-associated HIV RNA, and total DNA. Enrollment of 18 Fiebig I-III and 45 Fiebig IV-VI HIV clade C subjects occurred a median of 18 days after index blood donation. ART was administered successfully and compliance with follow-up visits was excellent. There were only minimal differences in HIV reservoir between ART initiation in Fiebig stages I-III vs. IV-VI, but ART noncompliance increased HIV reservoir. In 11 untreated HIV elite controllers, HIV reservoir levels were similar to or higher than those seen in our early treated cohort. National blood services can identify acute HIV cohorts for subsequent HIV cure research studies. Among HIV clade C-infected donors, HIV reservoir differed little by Fiebig stage at treatment initiation, but was smaller than in chronically treated HIV and those with ART noncompliance.

Indexed as

HIV-1HIV InfectionsHIV AntibodiesHumansRNAViral LoadHIV AntibodiesRNAblood donorsHIV clade CHIV cureHIV reservoirSouth Africa

Identifiers

PMID36366424
PMCPMC9698357
OpenAlexW4307192040

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.